Oncolytics Biotech® Inc.

10:02 AM EST - Oncolytics Biotech® Inc. : Announced the acceptance of an abstract highlighting new biomarker data from the randomized study NCI 8601: Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer. The data will be part of a poster presentation at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO, January 23 - 25, 2020, in San Francisco. Oncolytics Biotech® Inc. shares T.ONC are trading up $0.03 at $1.51.